What is Fenoswiss Forte 267 mg?
Fenoswiss Forte 267 mg (Fenoswiss Forte 267 mg) helps reduce cholesterol and triglycerides (fatty acids) in the blood. High levels of these types of fat in the blood are associated with an increased risk of atherosclerosis (clogged arteries).
Fenoswiss Forte 267 mg is used to treat high cholesterol and high triglyceride levels.
Fenoswiss Forte 267 mg may also be used for purposes not listed in this medication guide.
Fenoswiss Forte 267 mg indications
Primary Hypercholesterolemia or Mixed Dyslipidemia
Fenoswiss Forte 267 mg Capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Severe Hypertriglyceridemia
Fenoswiss Forte 267 mg Capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of Fenoswiss Forte 267 mg therapy on reducing this risk has not been adequately studied.
Important Limitations of Use
Fenoswiss Forte 267 mg at a dose equivalent to 150 mg was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus.
How should I use Fenoswiss Forte 267 mg?
Use Fenoswiss Forte 267 mg capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Some brands of Fenoswiss Forte 267 mg capsules should be taken with food. Some brands may be taken with or without food. Ask your pharmacist if you should take your brand of Fenoswiss Forte 267 mg capsules with food.
- Swallow Fenoswiss Forte 267 mg capsules whole. Do not open, crush, dissolve, or chew before swallowing. If you cannot swallow Fenoswiss Forte 267 mg capsules whole, tell your doctor. You may need a different medicine.
- Take Fenoswiss Forte 267 mg capsules with a full glass of water (8 oz [240 mL]).
- If you also take a bile acid-binding resin (eg, cholestyramine), do not take it within 4 to 6 hours before or 1 hour after taking Fenoswiss Forte 267 mg capsules. Check with your doctor if you have any questions.
- Take Fenoswiss Forte 267 mg capsules on a regular schedule to get the most benefit from it.
- Taking Fenoswiss Forte 267 mg capsules at the same time each day will help you remember to take it.
- Continue to take Fenoswiss Forte 267 mg capsules even if you feel well. Do not miss any doses.
- If you miss a dose of Fenoswiss Forte 267 mg capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Fenoswiss Forte 267 mg capsules.
Uses of Fenoswiss Forte 267 mg in details
Use: Labeled Indications
Hypercholesterolemia or mixed dyslipidemia: Adjunctive therapy to diet for the reduction of low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adults with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb). Use lipid-altering agents in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
Note: While FDA-approved for hypercholesterolemia, Fenoswiss Forte 267 mg is not a first- or second-line choice; other agents may be more suitable (ACC/AHA [Stone 2013]). In addition, use is not recommended to lower LDL-C or raise HDL-C in the absence of hypertriglyceridemia.
Hypertriglyceridemia: Adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).
Off Label Uses
Primary biliary cholangitis
Data from a single-center, retrospective cohort study support the use of Fenoswiss Forte 267 mg (in combination with ursodiol) in patients with primary biliary cholangitis (PBC) who have had an incomplete biochemical response to ursodiol monotherapy and showed significant improvement in alkaline phosphatase, a reduction in hepatic decompensation, and transplant-free survival improvement.
Fenoswiss Forte 267 mg description
Each film-coated tablet contains Fenofibrate BP 160 mg. It also contains the following excipients: Pregelatinized starch maize, povidone, sodium lauryl sulphate, microcrystalline cellulose, crospovidone, anhydrous colloidal silica, sodium stearyl fumarate, purified water and opadry AMB OY-B-28920.
Fenoswiss Forte 267 mg is a lipid-regulating agent. The empirical formula is C20H21O4Cl and the molecular weight is 360.83. Fenoswiss Forte 267 mg is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.
Fenoswiss Forte 267 mg dosage
Fenoswiss Forte 267 mg Dosage
Generic name: Fenoswiss Forte 267 mg 160mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The dose of Fenoswiss Forte 267 mg is 160 mg once daily.
Patients should be placed on an appropriate lipid-lowering diet before receiving Fenoswiss Forte 267 mg and should continue this diet during treatment with Fenoswiss Forte 267 mg.
Lipid levels should be monitored periodically. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment.
Fenoswiss Forte 267 mg tablets can be given without regard to meals. Patients should be advised to swallow Fenoswiss Forte 267 mg tablets whole. Do not crush, break, dissolve, or chew tablets.
More about Fenoswiss Forte 267 mg (Fenoswiss Forte 267 mg)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Fenoswiss Forte 267 mg
- Fenoswiss Forte 267 mg (Advanced Reading)
- Other brands: Fenoswiss Forte 267 mg, Lofibra, Lipofen, Fenoswiss Forte 267 mg, More (1) »
Professional resources
- Fenoswiss Forte 267 mg (FDA)
- Fenofibric Acid/Fenoswiss Forte 267 mg (AHFS Monograph)
Related treatment guides
- Hyperlipoproteinemia
- Hyperlipoproteinemia Type IIa, Elevated LDL
- Hyperlipoproteinemia Type IIb, Elevated LDL VLDL
- Hyperlipoproteinemia Type IV, Elevated VLDL
- Hyperlipoproteinemia Type V, Elevated Chylomicrons VLDL
- More (1) »
Fenoswiss Forte 267 mg interactions
See also:
What other drugs will affect Fenoswiss Forte 267 mg?
Coumarin Anticoagulants
Potentiation of coumarin-type anticoagulant effect has been observed with prolongation of the PT/INR.
Caution should be exercised when Fenoswiss Forte 267 mg is given in conjunction with coumarin anticoagulants. Fenoswiss Forte 267 mg may potentiate the anticoagulant effect of these agents resulting in prolongation of the PT/INR. To prevent bleeding complications, frequent monitoring of PT/INR and dose adjustment of the oral anticoagulant as recommended until the PT/INR has stabilized.
Immunosuppressants
Immunosuppressant agents such as cyclosporine and tacrolimus can impair renal function and because renal excretion is the primary elimination route of fibrate drugs including Fenoswiss Forte 267 mg capsules, there is a risk that an interaction will lead to deterioration of renal function. When immunosuppressants and other potentially nephrotoxic agents are co-administered with Fenoswiss Forte 267 mg capsules, the lowest effective dose of Fenoswiss Forte 267 mg capsules should be employed and renal function should be monitored.
Bile-Acid Binding Resins
Since bile-acid binding resins may bind other drugs given concurrently, patients should take Fenoswiss Forte 267 mg at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.
Colchicine
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing Fenoswiss Forte 267 mg with colchicine.
Fenoswiss Forte 267 mg side effects
See also:
What are the possible side effects of Fenoswiss Forte 267 mg?
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Fenofibric acid is the active metabolite of Fenoswiss Forte 267 mg. Adverse events reported by 2% or more of patients treated with Fenoswiss Forte 267 mg and greater than placebo during double-blind, placebocontrolled trials are listed in Table 1. Adverse events led to discontinuation of treatment in 5.0% of patients treated with Fenoswiss Forte 267 mg and in 3.0% treated with placebo. Increases in liver tests were the most frequent events, causing discontinuation of Fenoswiss Forte 267 mg treatment in 1.6% of patients in double-blind trials.
Table 1: Adverse Events Reported by 2% or More of Patients Treated with Fenoswiss Forte 267 mg and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials
| BODY SYSTEM Adverse Event | Fenoswiss Forte 267 mg* (N = 439) | Placebo (N = 365) |
| BODY AS A WHOLE | ||
| Abdominal Pain | 4.6% | 4.4% |
| Back Pain | 3.4% | 2.5% |
| Headache | 3.2% | 2.7% |
| DIGESTIVE | ||
| Nausea | 2.3% | 1.9% |
| Constipation | 2.1% | 1.4% |
| INVESTIGATIONS | ||
| Abnormal Liver Tests | 7.5% | 1.4% |
| Increased AST | 3.4% | 0.5% |
| Increased ALT | 3.0% | 1.6% |
| Increased Creatine Phosphokinase | 3.0% | 1.4% |
| RESPIRATORY | ||
| Respiratory Disorder | 6.2% | 5.5% |
| Rhinitis | 2.3% | 1.1% |
| * Dosage equivalent to 135 mg Fenoswiss Forte 267 mg |
Clinical trials with Fenoswiss Forte 267 mg did not include a placebo-control arm. However, the adverse event profile of Fenoswiss Forte 267 mg was generally consistent with that of Fenoswiss Forte 267 mg. The following adverse events not listed above were reported in ≥ 3% of patients taking Fenoswiss Forte 267 mg alone:
Gastrointestinal Disorders: Diarrhea, dyspepsia
General Disorders and Administration Site Conditions: Pain
Infections and Infestations: Nasopharyngitis, sinusitis, upper respiratory tract infection
Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia, pain in extremity
Nervous System Disorders: Dizzinesss
Postmarketing Experience
The following adverse events have been identified during postapproval use of Fenoswiss Forte 267 mg: rhabdomyolysis, pancreatitis, renal failure, muscle spasms, acute renal failure, hepatitis, cirrhosis, anemia, asthenia, and severely depressed HDL-cholesterol levels.
Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Fenoswiss Forte 267 mg contraindications
See also:
What is the most important information I should know about Fenoswiss Forte 267 mg?
Hypersensitivity to Fenoswiss Forte 267 mg or fenofibric acid or to any of the excipients of Fenoswiss Forte 267 mg.
Severe renal impairment/insufficiency, including those receiving dialysis.
Active liver disease/dysfunction/insufficiency, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities eg, persistent elevations in serum transaminases. Pre-existing gallbladder disease.
Photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen.
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia.
Fenoswiss Forte 267 mg contains lecithin soya as an excipient and therefore, Fenoswiss Forte 267 mg should not be taken with allergic to peanut or arachis oil or soya lecithin, or related products due to the risk of hypersensitivity reactions.
Use in lactation: Fenoswiss Forte 267 mg should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue Fenoswiss Forte 267 mg, taking into account the importance of Fenoswiss Forte 267 mg to the mother. There are no data on the excretion of Fenoswiss Forte 267 mg and/or its metabolites into breast milk.
Use in children: Safety and effectiveness in pediatric patients aged <18 years have not been established.
Active ingredient matches for Fenoswiss Forte 267 mg:
Fenofibrate in Hungary.
List of Fenoswiss Forte 267 mg substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Fenoswiss 160 mg (Hungary) | |
| Fenotard | |
| Fenothyl (Tunisia) | |
| Fenotor | |
| Fenotor 145mg Tablet (Prevento Pharma) | $ 0.12 |
| Fernolid (Vietnam) | |
| Fernolid 200 mg x 4 Blister x 10 Tablet | |
| Fibra (Pakistan) | |
| Fibrafen (Philippines) | |
| Fibrafen 200M 200 mg x 30's (Patriot) | $ 35.30 |
| Fibrafen 200M (Philippines) | |
| Fibral (India, Myanmar) | |
| FIBRAL Capsule/ Tablet / 200mg / 10 units (Cardicare (Micro Labs Ltd)) | $ 0.99 |
| Fibral 200mg CAP / 10 (Cardicare (Micro Labs Ltd)) | $ 0.82 |
| 200 mg x 10's (Cardicare (Micro Labs Ltd)) | $ 0.82 |
| Fibral 200 mg Tablet (Cardicare (Micro Labs Ltd)) | $ 0.11 |
| FIBRAL 200 MG CAPSULE 1 strip / 10 capsules each (Cardicare (Micro Labs Ltd)) | $ 1.43 |
| FIBRAL cap 200 mg x 10's (Cardicare (Micro Labs Ltd)) | $ 0.82 |
| Fibral 200mg Capsule (Cardicare (Micro Labs Ltd)) | $ 0.14 |
| Fibramed (Indonesia) | |
| Fibramed 300 mg x 5 x 6's (Promed) | $ 22.32 |
| Fibranor (Bulgaria) | |
| Fibrate (India) | |
| Fibrate 200mg CAP / 10 (Avinash Health Products Pvt Ltd) | $ 0.84 |
| 200 mg x 10's (Avinash Health Products Pvt Ltd) | $ 0.84 |
| Fibrate 200 mg Capsule (Avinash Health Products Pvt Ltd) | $ 0.08 |
| FIBRATE 200 MG TABLET 1 strip / 10 tablets each (Avinash Health Products Pvt Ltd) | $ 1.02 |
| FIBRATE cap 200 mg x 10's (Avinash Health Products Pvt Ltd) | $ 0.84 |
| Fibrate 200mg Tablet (Avinash Health Products Pvt Ltd) | $ 0.10 |
| Fibre (Bangladesh) | |
| Tablet; Oral; Fiber 500 mg | |
| Fibril (Bangladesh, Philippines, Thailand) | |
| FIBRIL Granules/ Powder / 65%w/w / 100gm units (Pinnacle (Lupin Laboratories Ltd.)) | $ 0.66 |
| Fibril 100 mg x 100's (Pinnacle (Lupin Laboratories Ltd.)) | $ 20.41 |
| Fibril 160 mg x 3 x 10's (Pinnacle (Lupin Laboratories Ltd.)) | |
| 65 % w/w x 100g (Pinnacle (Lupin Laboratories Ltd.)) | $ 0.66 |
| Fibril 100 gm Powder (Pinnacle (Lupin Laboratories Ltd.)) | $ 0.13 |
| Fibril cap 160 mg 3 x 10's (Pinnacle (Lupin Laboratories Ltd.)) | |
| FIBROFEN | |
| FIBROFEN 160 MG TABLET 1 strip / 10 tablets each (Orchid Chemicals & Pharmaceuticals Ltd) | $ 0.64 |
| Fibrofen 160mg Tablet (Orchid Chemicals & Pharmaceuticals Ltd) | $ 0.06 |
| Fibronil (Chile) | |
| Finabate (India) | |
| Finabate 145mg TAB / 10 (Johnlee (Vista)) | $ 1.14 |
| Finabate 160mg TAB / 10 (Johnlee (Vista)) | $ 1.33 |
| Finabate 200mg TAB / 10 (Johnlee (Vista)) | $ 1.81 |
| FINABATE tab 145 mg x 10's (Johnlee (Vista)) | $ 1.14 |
| FINABATE tab 160 mg x 10's (Johnlee (Vista)) | $ 1.33 |
| FINABATE tab 200 mg x 10's (Johnlee (Vista)) | $ 1.81 |
| Finabate 160mg Tablet (Johnlee (Vista)) | $ 0.13 |
| Finabrat 100/300 (Vietnam) | |
| Finabrat 100/300 100 mg x 4 Blister x 12 Tablet | |
| Finabrat 100/300 300 mg x 3 Blister x 10 Tablet | |
See 1103 substitutes for Fenoswiss Forte 267 mg | |
References
- DailyMed. "FENOFIBRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "fenofibrate". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "fenofibrate". http://www.drugbank.ca/drugs/DB01039 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Fenoswiss Forte 267 mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Fenoswiss Forte 267 mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
